

## Preliminary Programme

Basel, Switzerland  
9-11 October 2025

Thursday, 9 October 2025

13:00 – 14:00	<b>Session I: Pathogenesis of acquired AA</b> <b>Chairs:</b> <i>Ted Gordon-Smith (UK)</i>	
13:00 – 13:20	From a genetic point of view	Marcin Wlodarski (DE)
13:20 – 13:40	From an immunology point of view	Leo Hansmann (DE)
13:40 – 14:00	HLA and AA: Friends or Foe	
14:00 – 15:30	<b>Session II: 30 years in AA – What have we learned</b> <b>Chairs:</b>	
14:00 – 14:20	Diagnosis	Alicia Rovo (CH)
14:20 – 14:40	Treatment I: Transplantation	
14:40 – 15:00	Treatment II: IST	Jakob Passweg (CH)
15:00 – 15:20	Late effects	
15:20 – 15:30	Discussion: What have learned in 30 years	
15:30 – 16:00	<b>Coffee Break</b>	
16:00 – 16:45	<b>Industry Symposium Slot</b>	
16:45 – 17:45	<b>Session III: Inherited BMFs: HCT Versus gene therapy</b> <b>Chairs:</b> <i>Carlo Dufour (IT) &amp; Constantijn Halkes (NL)</i>	
16:45 – 17:05	Role of HCT in inherited BMFs	Eliane Gluckman (FR)
17:05 – 17:25	Gene Therapy in inherited BMFs	
17:25 – 17:45	Genetic counselling of families (patients and donor!) with inherited BMFs	
20:00 – 22:00	<b>Scientific Business Meeting</b>	

## Preliminary Programme

Basel, Switzerland  
9-11 October 2025

Friday, 10 October 2025

09:00 – 10:00

### Session IV: Complement

**Chairs:** *Camilla Frieri (IT) & Jaroslaw Maciejewski (US)*

09:00 – 09:20

Complement and disease

09:20 – 09:40

Other complement – associated diseases / Benefits of complement inhibitors in other indications

09:40 – 10:00

Discussion: complement and transplant/more

10:00 – 11:00

### Session V: Daily hurdles in AA

**Chairs:**

10:00 – 10:20

Tapering EPAG – How, when and when to re-start again...

10:20 – 10:34

Work up and treatment of MAA (Results of EMAA)

10:40 – 11:00

How to distinguish “clonal haematopoiesis” from “transformation” in AA

Beatrice Drexler (CH)

Britta Höchsmann (DE)

Daria Babushok (US)

11:00 – 11:30

### Coffee Break

11:30 – 12:45

### Session VI: Initiative session

**Chairs:**

11:30 – 11:55

ICARIIS initiative

11:55 – 12:20

ASH AA guidelines

12:20 – 12:45

Status of art: HCT versus IST (SAAWP initiatives)

12:45 – 13:30

### Lunch Break

13:30 – 14:15

### Industry Symposium kindly sponsored by Novartis

14:15 – 15:30

### Session VII: PNH

**Chairs:**

14:15 – 14:35

Therapeutic algorithm in 2025 for PNH

14:35 – 14:55

HSCT in PNH

14:55 – 15:15

Future directions in PNH

15:15 – 15:30

Discussion

Morag Griffin (UK)

Camilla Frieri (IT)

15:30 – 16:00

### Coffee Break

16:00 – 17:15

### Session VIII: The patients, the nurses and caregivers perspective

**Chairs:** *Britta Hochsmann (DE)*

16:00 – 16:25

Deciphering fatigue in AA/PNH for future care

16:25 – 16:50

Transition of AA patients

16:50 – 17:15

Infectious risk in AA patients

Pascale Burmester (DE)

## Preliminary Programme

Basel, Switzerland  
9-11 October 2025

### Saturday, 11 October 2025

09:00 – 10:00	<b>Session IX: Deciphering acquired versus inherited BMFs in 2025</b> <b>Chairs:</b> <i>Maurizio Miano (IT) &amp; Alicia Rovó (CH)</i>	
09:00 – 09:20	From the pediatric perspective	Carlo Dufour (IT)
09:20 – 09:40	From the adults perspective	
09:40 – 10:00	New germline kids on the block in 2025	Marcin Wlodarski (DE)
10:00 – 11:00	<b>Session X: Long-term outcome</b> <b>Chairs:</b>	
10:00 – 10:20	Long term outcome in IST versus HCT	Beatrice Drexler (CH)
10:20 – 10:40	How to follow up on inherited BMF to detect “transformation”	Fabian Beier (DE)
10:40 – 11:00	How to follow up on QoL in AA?	
11:00 – 11:30	<b>Coffee Break</b>	
11:30 – 12:30	<b>Session XI: Future Directions</b> <b>Chairs:</b> <i>Beatrice Drexler (CH)</i>	
11:30 – 11:50	Finding the individual trigger in acquired AA	Jaroslav Maciejewski (US)
11:50 – 12:10	New kids on the block (Ruxo, Tregs, ...)	
12:10 – 12:30	Machine learning & artificial intelligence in the diagnosis and risk stratification of AA	Shreyans Gandhi (UK)